Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection
Immune protection following either vaccination or infection with SARS-CoV-2 is thought to decrease over time. We designed a retrospective study, conducted at Leumit Health Services in Israel, to determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals. Antibody titers were measured between 31 January 2021, and 31 July 2021 in two mutually exclusive groups: (i) vaccinated individuals who received two doses of BNT162b2 vaccine and had no history of previous infection with COVID-19 and (ii) SARS-CoV-2 convalescents who had not received the vaccine. A total of 2653 individuals fully vaccinated by two doses of vaccine during the study period and 4361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated individuals (median 1581 AU/mL IQR [533.8-5644.6]) after the second vaccination than in convalescent individuals (median 355.3 AU/mL IQR [141.2-998.7]; p < 0.001). In vaccinated subjects, antibody titers decreased by up to 38% each subsequent month while in convalescents they decreased by less than 5% per month. Six months after BNT162b2 vaccination 16.1% subjects had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection. This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group.
Errataetall: | |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Vaccines - 10(2021), 1 vom: 31. Dez. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Israel, Ariel [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibody titer |
---|
Anmerkungen: |
Date Revised 28.01.2022 published: Electronic UpdateOf: medRxiv. 2021 Aug 21;:. - PMID 34462761 Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/vaccines10010064 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM335973175 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM335973175 | ||
003 | DE-627 | ||
005 | 20231225231057.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/vaccines10010064 |2 doi | |
028 | 5 | 2 | |a pubmed24n1119.xml |
035 | |a (DE-627)NLM335973175 | ||
035 | |a (NLM)35062724 | ||
035 | |a (PII)64 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Israel, Ariel |e verfasserin |4 aut | |
245 | 1 | 0 | |a Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 28.01.2022 | ||
500 | |a published: Electronic | ||
500 | |a UpdateOf: medRxiv. 2021 Aug 21;:. - PMID 34462761 | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Immune protection following either vaccination or infection with SARS-CoV-2 is thought to decrease over time. We designed a retrospective study, conducted at Leumit Health Services in Israel, to determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals. Antibody titers were measured between 31 January 2021, and 31 July 2021 in two mutually exclusive groups: (i) vaccinated individuals who received two doses of BNT162b2 vaccine and had no history of previous infection with COVID-19 and (ii) SARS-CoV-2 convalescents who had not received the vaccine. A total of 2653 individuals fully vaccinated by two doses of vaccine during the study period and 4361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated individuals (median 1581 AU/mL IQR [533.8-5644.6]) after the second vaccination than in convalescent individuals (median 355.3 AU/mL IQR [141.2-998.7]; p < 0.001). In vaccinated subjects, antibody titers decreased by up to 38% each subsequent month while in convalescents they decreased by less than 5% per month. Six months after BNT162b2 vaccination 16.1% subjects had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection. This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a BNT162b2 mRNA vaccine | |
650 | 4 | |a SARS-CoV-2 infection | |
650 | 4 | |a antibody titer | |
700 | 1 | |a Shenhar, Yotam |e verfasserin |4 aut | |
700 | 1 | |a Green, Ilan |e verfasserin |4 aut | |
700 | 1 | |a Merzon, Eugene |e verfasserin |4 aut | |
700 | 1 | |a Golan-Cohen, Avivit |e verfasserin |4 aut | |
700 | 1 | |a Schäffer, Alejandro A |e verfasserin |4 aut | |
700 | 1 | |a Ruppin, Eytan |e verfasserin |4 aut | |
700 | 1 | |a Vinker, Shlomo |e verfasserin |4 aut | |
700 | 1 | |a Magen, Eli |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 10(2021), 1 vom: 31. Dez. |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2021 |g number:1 |g day:31 |g month:12 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines10010064 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 10 |j 2021 |e 1 |b 31 |c 12 |